Morning Overview on MSN
A new genomic test could spare two-thirds of high-risk breast cancer patients from chemotherapy entirely, per ASCO 2026 results
Thousands of women diagnosed with high-risk, estrogen-receptor-positive breast cancer may no longer need chemotherapy, ...
Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx to ...
A new DNA test could spare millions of breast cancer patients from chemotherapy. We answer your questions about what it means ...
Findings from a study of Veracyte’s Prosigna genomic assay and GRAIL’s multi-cancer early detection test were presented at ...
(Nasdaq: VCYT), a leading cancer diagnostics company, today announced the U.S. commercial launch of the Prosigna® Breast Risk of Recurrence (ROR) test, a genomic test for patients diagnosed with early ...
94.8% of those who received chemotherapy alongside hormone therapy were alive and free from breast cancer recurrence 93.6% of those treated with hormone therapy alone were also alive and ...
A genomic test could help thousands of breast cancer patients avoid chemotherapy without compromising their outcomes, according to results from a large international phase III clinical trial presented ...
The Prosigna test reads 50 genes in a breast tumor and sorts people into low, medium, or high risk of cancer coming back.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results